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Abstract
The exquisite soft-tissue contrast of magnetic resonance imaging (MRI) has meant that the technique is
having an increasing role in contouring the gross tumor volume (GTV) and organs at risk (OAR) in
radiation therapy treatment planning systems (TPS). MRI-planning scans from diagnostic MRI scanners
are currently incorporated into the planning process by being registered to CT data. The soft-tissue data
from the MRI provides target outline guidance and the CT provides a solid geometric and electron density
map for accurate dose calculation on the TPS computer. There is increasing interest in MRI machine
placement in radiotherapy clinics as an adjunct to CT simulators. Most vendors now offer 70 cm bores
with flat couch inserts and specialised RF coil designs. We would refer to these devices as MRsimulators. There is also research into the future application of MR-simulators independent of CT and as
in-room image-guidance devices. It is within the background of this increased interest in the utility of MRI
in radiotherapy treatment planning that this paper is couched. The paper outlines publications that deal
with standard MRI sequences used in current clinical practice. It then discusses the potential for using
processed functional diffusion maps (fDM) derived from diffusion weighted image sequences in tracking
tumor activity and tumor recurrence. Next, this paper reviews publications that describe the use of MRI in
patient-management applications that may, in turn, be relevant to radiotherapy treatment planning. The
review briefly discusses the concepts behind functional techniques such as dynamic contrast enhanced
(DCE), diffusion-weighted (DW) MRI sequences and magnetic resonance spectroscopic imaging (MRSI).
Significant applications of MR are discussed in terms of the following treatment sites: brain, head and
neck, breast, lung, prostate and cervix. While not yet routine, the use of apparent diffusion coefficient
(ADC) map analysis indicates an exciting future application for functional MRI. Although DW-MRI has not
yet been routinely used in boost adaptive techniques, it is being assessed in cohort studies for subvolume boosting in prostate tumors.
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The exquisite soft-tissue contrast of magnetic resonance imaging (MRI) has meant that the
technique is having an increasing role in contouring the gross tumor volume (GTV) and organs
at risk (OAR) in radiation therapy treatment planning systems (TPS). MRI-planning scans
from diagnostic MRI scanners are currently incorporated into the planning process by being
registered to CT data. The soft-tissue data from the MRI provides target outline guidance and
the CT provides a solid geometric and electron density map for accurate dose calculation on
the TPS computer. There is increasing interest in MRI machine placement in radiotherapy
clinics as an adjunct to CT simulators. Most vendors now offer 70 cm bores with flat couch
inserts and specialised RF coil designs. We would refer to these devices as MR-simulators.
There is also research into the future application of MR-simulators independent of CT and as
in-room image-guidance devices. It is within the background of this increased interest in the
utility of MRI in radiotherapy treatment planning that this paper is couched. The paper outlines
publications that deal with standard MRI sequences used in current clinical practice. It then
discusses the potential for using processed functional diffusion maps (fDM) derived from
diffusion weighted image sequences in tracking tumor activity and tumor recurrence. Next,
this paper reviews publications that describe the use of MRI in patient-management applications that may, in turn, be relevant to radiotherapy treatment planning. The review briefly
discusses the concepts behind functional techniques such as dynamic contrast enhanced
(DCE), diffusion-weighted (DW) MRI sequences and magnetic resonance spectroscopic
imaging (MRSI). Significant applications of MR are discussed in terms of the following treatment sites: brain, head and neck, breast, lung, prostate and cervix. While not yet routine, the
use of apparent diffusion coefficient (ADC) map analysis indicates an exciting future application for functional MRI. Although DW-MRI has not yet been routinely used in boost adaptive
techniques, it is being assessed in cohort studies for sub-volume boosting in prostate tumors.
Key words: MRI; Radiation therapy; Radiation; Therapy treatment planning.
Abbreviations: ADC: Apparent Diffusion Coefficient; AVM: Arteriovenous Malformation; BOLD:
Blood Oxygen Level Dependent; CC: Corpus Carvernosum; CT: Computed Tomography; CTV:
Clinical Target Volume; 4DCT: 4 Dimensional Computed Tomography; DW: Diffusion Weighted;
DCE: Dynamic Contrast Enhanced; DNP: Dynamic Nuclear Polarization; EPI: Echo Planar Imaging;
fDM: Functional Diffusion Map; fV: Functional Lung Volume; FFE-EPI: Fast Field Echo Planar
Imaging; FIESTA: Fast Image Employing Steady State Acquisition; FLASH: Fast Low Angle Shot;
FLAIR: Fast Fluid-attenuated Inversion Recovery; fMRI: Functional Magnetic Resonance Imaging;
FSRT: Fractionated Stereotactic Radiation Therapy; GTV: Gross Tumor Volume; HNSCC: Head
and Neck Squamous Cell Carcinioma; IGBT: Image Guided Brachytherapy; IPA: Internal Pudental Artery; MRA: Magnetic Resonance Angiography; MRI: Magnetic Resonance Imaging; MRSI:
Magnetic Resonance Spectroscopic Imaging; NSCLC: Non Small Cell Lung Cancer; PET: Positron
Emission Tomography; PHIP: Parahydrogen Induced Polarization; PTV: Planning Target Volume;
SPGR: Spoiled Gradient; SSFSE: Single Shot Fast Spin Echo; SRS: Stereotactic Radiosurgery; T1:
Longitudinal Relaxation Time; T2: Transverse Relaxation Time; TB: Tumor Bed; TPS: Treatment
Planning System; TR: Repetition Time; TrueFIST: True Fast Imaging with Steady State Precession;
VMAT: Volumetric Modulated Arc Therapy.
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Introduction
Developments in the field of radiotherapy such as intensitymodulated radiation therapy (IMRT), volumetric modulated
arc therapy (VMAT) and tomotherapy have provided the
means to deliver highly conformal treatments offering the
promise of improved sparing of normal tissue and escalation of tumor dose. For these techniques to achieve their full
potential there is an increasing need for anatomical and functional imaging to be used at the planning stage, and ideally as
a verification tool throughout radiotherapy to localise disease
with a high level of accuracy.
Computed tomography (CT) for imaging uses ionizing
x-rays, and hence carries some stochastic increased risk in
induction of a second primary malignancy from the ionizing
radiation (1). While the risk of a single CT scan for planning is extremely small this risk is increased with repeat CT
imaging in such scenarios as adaptive replanning in the radiotherapy setting and with prolonged survival. Because MRI
does not rely on ionizing radiation for imaging, there is no
increased potential induction of secondary primary malignancies associated with its use.
Magnetic resonance imaging (MRI) is a non-ionising technique that uses a strong magnetic field to provide high-
resolution anatomical information with excellent soft-tissue
contrast. By using specific MRI techniques, functional information such as tumor perfusion vascular permeability, extracellular space tortuosity, metabolic status and hypoxia can
also be obtained (2).
Development of MRI-Cobalt (ViewRay™) and MRI-linac
prototypes is underway. It is envisaged these will enable
MRI to be used for on-line image-guided radiation therapy
(IGRT) (3, 4). The production of combined MRI-linacs is not
trivial. Apart from the engineering challenges of RF perturbation from the linac, there is the requirement to account for
various electron-beam perturbation effects that affect dose at
regions of air and lung-tissue interface (5). There has also
been a feasibility study into the use of MRI in image guidance for proton machines (6).
The focus of this review article is to provide some insight
into the current role of MRI in radiation-therapy treatment
planning. A future enhancement of this role is explored by
examining clinical trials data of various cancer-treatment
sites, sequences and analysis methods, such as functional
MRI, that are currently applied to cancer management.
Methods
Current literature has been reviewed using Medline and
Google scholar to establish the MRI sequences that have been
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considered for radiotherapy treatment planning purposes, and
MRI sequences that show potential for future use. The use of
MRI for radiation therapy treatment planning purposes has
been considered across all clinical sites, with a more detailed
review of the use of MRI in radiotherapy treatment planning
for six clinical sites.
The first section of the results presents definitions and basic
acquisition details for standard MRI sequences and imaging
analysis methods used for, or considered for future use in,
radiotherapy treatment planning. This provides a series of
definitions that help with the discussion about sequences and
analysis methods used in current MRI clinical practice and trials, and includes concepts behind functional techniques such
as dynamic contrast enhanced (DCE), diffusion-weighted
(DW) MRI sequences and magnetic resonance spectroscopic
imaging (MRSI).
The second section of the results discusses significant applications of MR in terms of the following treatment sites: brain,
head and neck, breast, lung, prostate and cervix
Results
MRI sequences that have been considered for, or show potential for use in, radiotherapy treatment planning.
The most commonly used of the MR-visible nuclei is the
hydrogen proton, which produces the strongest signal and is
abundant in the body (primarily as water and fat). By changing the sequence parameters, MR images exploit the differences in either “longitudinal” (T1) or “transverse” (T2)
relaxation times of fat and water, producing large variations
in contrast.
In general, T1-weighted images are considered best for gross
structural information (anatomy) and T2-weighted images
for biological characteristics that may aid with pathology
information. However, while extremely useful in many
clinical applications and for diagnosis, neither of these imaging methods provides sensitive or specific diagnosis and
localization of either prostate or breast cancer (7, 8). This
is because the tissue properties that give rise to differences
in T1 and T2 are not closely related to the tissue structural
features that define cancer. This shortcoming also applies
to CT, which reconstructs images from attenuation maps of
x-ray projections, and hence essentially tracks tissue-density
changes (9, 10). There is, however, more potential to enhance
MRI sequences, providing functional data to ascertain more
clinical information such as tumor response than possible
with CT. Some of the more exciting advanced techniques
are outlined in this paper; many fall within the realm of so
called “functional MRI”. Hence this term has been adopted
(and used here) to describe any MRI technique capable
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of demonstrating information in addition to the anatomical images more routinely acquired (11-13). As a general
description, functional MRI is used to define techniques that
probe the status of the tumor itself. Some of the most relevant
examples for radiotherapy are described briefly below.
Dynamic Contrast Enhanced MRI (DCE-MRI)
DCE-MRI is performed by sequential imaging following
the injection of a suitable paramagnetic contrast agent (usually some gadolinium-based chelate). Fast gradient-echo
sequences are used to image each slice as fast as possible with
temporal resolutions of 2-10 s for 2D techniques and around
30 s for 3D volumetric data. By using T2* images, data on
tissue perfusion and blood volume can be extracted. By using
sequences sensitive to the presence of contrast medium, T1
methods can be used to evaluate the extravascular extracellular space. Information on micro-vessel perfusion, permeability and extracellular leakage space can also be obtained.
The vast amount of imaging data produced by these methods may be viewed in a cine format either with or without
pre-contrast subtraction. Regions-of-interest may be interrogated to produce enhancement-time curves with malignant
tumors demonstrating a rapid wash-in and wash-out of contrast. Alternatively simple empirical measures such as peak
enhancement or wash-in rate can be produced on a pixel-bypixel basis to provide parameter maps. More sophisticated
models look to establish real physiological parameters from
these datasets (14). DCE-MRI has been shown to have diagnostic value in various tumors, and correlates with the therapy effect of standard chemotherapy and radiotherapy (2).
Diffusion-Weighted MRI (DW-MRI)
DW-MRI scan sequences produce image contrast that
depends on differences in tissue-water mobility. Two equally
large, opposing gradient pulses in the diffusion sequence
make the signal intensity dependent on the movement of
water molecules. The first gradient pulse induces a phase shift
of water molecules, followed by incomplete rephasing after
the second gradient pulse, with the phase difference depending on the mobility of the water molecules. Incomplete
rephasing of water molecules is less pronounced in hypercellular tissue, characterized by less signal loss; rephasing
is more pronounced in hypo-cellular tissue, which shows
increased signal loss (15). The apparent diffusion coefficient
(ADC), in units mm2/s, is the quantitative parameter used for
the assessment of water diffusion through tissue. The term
apparent reflects the concept that the measurement is subject
to other factors not just water mobility. The sensitivity of the
gradient scheme is defined by its “b-value”: by acquiring at
least two images with different b values (usually b 5 0 and
b 5 1000 s mm22) the ADC can be measured directly. The
mean ADC values in the benign and malignant Head and
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Neck lesions have been observed as 1.51 3 1023 mm2/s and
1.07 3 1023 mm2/s , respectively (16).
In biologic tissues, the movement of water molecules is
restricted because their motion is modified and limited by
interactions with cell membranes and macromolecules.
There is an inverse correlation between the degree to which
the motion of the water is restricted and the tissue cellularity.
This inverse correlation also applies to the integrity of the
cell membrane. Hence in a tumor with high cellularity, the
motion of water molecules is more restricted. On the other
hand, when a tumor has a high glandular component or has
significant necrosis, there is less restriction of motion. In
general, treatments inducing apoptosis (e.g., chemotherapy)
result in increased ADC values due to cell swelling, tumor
lysis and necrosis (2).
In adenocarcinoma of the breast and prostate, for example,
cancer development is characterized by the proliferation of
epithelial cells and the loss of normal tissue architecture.
An imaging method that generates contrast based on microscopic tissue structural properties would be expected to
provide cancer detection and staging, such that the contrast
can be made to reflect the structures that define pathology.
DW-MRI is an ideal candidate for this purpose because the
free diffusion of water in tissue is known to be constrained
by cellular structures and cell walls. This property has been
used extensively in the study of neural tissue; the concept
also been reported in cohort studies of head and neck cancer
cases, but has had only limited clinical application to diseases of glandular tissue such as breast and prostate (15).
Pathologic prostate samples have also been examined at
very high resolution (nominally 40 microns) in vitro in high
field MR (16 T) and the lymphatic structures may be a confounding factor for ADC analysis at typical clinical voxel
resolutions (17).
Diffusion-weighted imaging is probably the most useful
new tool in tumor response, and cohort studies show its
potential in providing evidence of tumor recurrence. One of
the challenges with these sequences is that image-distortion
artifacts are apparent in some of these sequences. Thus,
defining regions of tumor burden may need some form of
deformable registration to other MRI sequenced images or
CT images if these potential volumes of recurrence are to
be targeted with extra radiation treatment doses to selective
intra-GTV regions by dose painting (18) or risk-adaptive
boosting (19).
Magnetic Resonance Spectroscopic Imaging (MRSI)
MR spectroscopy provides chemical information about tissue metabolites, commonly using the MR visible nuclei
of hydrogen (1H), phosphorus 31 (31P), fluorine 19 (19F)
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or 
carbon 13 (13C). Each specific nucleus exhibits a
slight change in processional frequency that depends on
its chemical environment. Specifically, variations in the
electron shielding of different molecules alter the magnetic field and resonant frequency (the chemical shift).
An MR spectrum is a kind of molecular fingerprint and
may contain many peaks at specific frequencies (or chemical shifts), one for each chemically distinguishable site or
group in a given metabolite or for specific sites in a variety
of metabolites (2).
The technique can be extended to MRSI, whereby spectra
are acquired from multiple contiguous volumes (voxels),
and peak areas or ratios are displayed with a color wash
overlying the anatomy to provide a metabolic map. The
small concentrations of metabolites necessitate the use of
large voxels, and resolution can be as much as an order of
magnitude poorer than in conventional imaging. Nevertheless, MRSI has been found to be useful in quantifying brain
function and brain-related cancerous tumors where the relative amount of NAA to choline (related to cell turnover) is
informative. In the prostate, the ratio of citrate to choline or
choline1creatine is used in a similar manner.
Lactate has been found to be indicative of hypoxia, and could
therefore be used to mark out radio resistance. However
Lactate can not currently be analysed accurately in vivo for
prostate cancer. This biomarker can only currently be visualized in prostate pathology samples ex-vivo at higher field
strengths. Lactate has been successfully identified from lipids
in head and neck and brain tumors with recent in vivo patient
techniques (20).
Some degree of expertise is required to interpret the data,
and the incorporation of this information into the planning
system is still in its infancy. Another challenge when imaging hypoxic regions is that hypoxic zones may be chronic
or acute, and may change position over time. As this article
does not focus on MRSI in great detail, the reader is guided
to an excellent review on its use in brain, breast and prostate
cancer (21).
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gradient steps very rapidly in one single repetition. However,
nerve stimulation provides a physiological limit to gradient
speed and has necessitated other developments with the aim
of faster imaging. In the last several years parallel imaging
has become available on all commercial systems: it substitutes some of the gradient steps with information provided
from RF coil sensitivity profiles. All these techniques have
combined to allow MRI to acquire sub-second images, and
have opened the technique up to a number of challenging
areas. These fast sequences may be critical to future IGRT
applications of MRI.
Hyperpolarization
The sensitivity of MRI and MRSI can be increased 1,000
to 10,000 times using hyperpolarization, whereby a sample
containing nuclei that had their spin population temporarily driven to a very high degree of polarization is introduced
into the body. Procedures to probe pathological defects have
been optimized for two noble-gas isotopes that can be inhaled
into the human lung: helium 3 (3He) and xenon 129 (129Xe).
An optical (laser) pumping technique is used to hyperpolarize the orbital electrons of alkali metal atoms, e.g., rubidium,
through angular-momentum transfer. This polarization is
then transferred to the nuclear spin system of the gas through
direct atomic contact. Once mixed with oxygen in the lung,
the half-life of the hyperpolarised signal is extremely short,
meaning the fast imaging strategies previously described
become of vital importance.
A number of lung-function medical conditions can benefit
from functional imaging using 3He MRI, as reviewed by
Fain et al. (23). For example, these images have been used
for conformal avoidance of lung tissue that is the most active
in gas exchange, as shown by 3He scans. Figure 1 shows
such a high-activity region of 3He uptake in orange (right)
fused to an MRI proton density scan image (left). The orange
region could then potentially be set as a threshold level, then
contoured for conformal avoidance during the radiotherapy
treatment planning process (24). Xenon has the added advantage that its transport into the lung tissue can be detected as a
chemical shift change with MRSI.

Fast Sequences
MRI is an inherently slow technique compared to CT, requiring numerous applications of imaging gradients to obtain
the desired “k-space” data; the faster these gradients can
be switched on and off, the faster the scan can be acquired.
T2-weighted spin-echo sequences, with long repetition times
(TR), are inherently slower than T1-weighted gradient echoes,
which are often used as the basis for rapid imaging (22). Both
types of sequences can be performed using segmented and
partial k-space strategies to improve imaging speed. Singleshot techniques, like eco planar imaging (EPI), apply all the

Hyperpolarization also has a role to play in 13C spectroscopy in the study of tumor metabolism, although this still
remains a research tool. Its low natural abundance means a
13
C-labeled tracer can be introduced into the body with little
baseline contamination. Its low sensitivity can be increased
dramatically with techniques such as dynamic nuclear
polarization (DNP) and parahydrogen induced polarization (PHIP) (25, 26). Unlike PET tracers, which are mainly
analogues of metabolites, 13C tracers undergo metabolic
changes and can be studied as they alter the appearance of
the MR spectrum.
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Figure 1: 3He polarization image showing polarized MR helium 3 diffusion scan (right) fused on a proton-density-weighted MR scan (left). These active
zones would be the regions of conformal avoidance, defined as low-dose objectives during the radiotherapy treatment planning process.

Site-specific Use of MRI in Radiotherapy
Treatment Planning
This section reviews clinical trials of sites for which various MRI sequences and analysis methods have been useful
in cancer management. The sites selected for review cover
brain, head and neck, breast, lung, prostate and cervix, and
are not intended to be exhaustive.

MRI is well established as the superior imaging modality
for diagnostic purposes when assessing the brain. In the
brain, MRI often provides better visualization of tumor
and normal tissue than CT, and hence the target volume for
high-precision intracranial radiotherapy is commonly delineated directly on MRI studies (Figure 2). It can be imaged
in standard diagnostic RF coils usually in the treatment
position, and its registration to CT is trivial even with differences in position.

Brain
Owing to its small size and central location within the magnet, the brain is one of the easiest organs to image well.

The brain was the first site where MRI was routinely used
in treatment planning. Routine clinical use of MRI in the
treatment-planning process of fractionated radiotherapy (RT),

Figure 2: CT (left) co-registered with a T1-3D-SPGR MRI image set (right). The difference in tumor visualization can be clearly appreciated.
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fractionated stereotactic radiotherapy (FSRT), stereotactic
radiosurgery (SRS) and functional radiosurgery (FSRS) has
been found to be a useful tool in brain tumors.
The treatment target for a patient having a high-grade
glioma can be determined from both a contrast-enhanced
T1-weighted high-resolution 3D spoiled-gradient (SPGR)
image as well as either a standard T2 MR image (27)
or a fast fluid-attenuated inversion recovery (FLAIR)
image (28). The T1-weighted high-resolution 3D SPGR is
used to define the gross visible disease, which is the region
of the blood-brain barrier breakdown, while the clinical target volume is defined using the T2-weighted image
series on which the extent of the oedema thought to harbor
microscopic disease is delineated. On the other hand, for
benign lesions as well as brain metastases that do not
invade the normal brain parenchyma, a contrast-enhanced
T1-weighted 3D SPGR is sufficient for target definition in
FSRT and SRS (29).
In the treatment of arteriovenous malformations (AVMs),
magnetic resonance angiography (MRA) is employed for
the definition of the nidus, which most of the time cannot be
clearly appreciated on T1-weighted MR images (30). Moreover, in the treatment of trigeminal neuralgia using functional
stereotactic radiosurgery, 3D fast imaging employing steadystate acquisition (FIESTA) MRI is employed for visualization and targeting of the involved trigeminal nerve 4 mm
from the root entry zone. Since this imaging technique has a
significant T2-weighting, the cerebral spinal fluid around the
brain stem luminates while normal brain and cranial nerves
appear almost black. This allows delineation of the involved
trigeminal nerve root as it emanates from the brainstem (31)
(Figure 3).
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To explore the potential to reliably compare intra- and posttreatment images with pre-treatment images on a voxelby-voxel basis, i.e. using voxel-based functional diffusion
maps at various time points to predict the response of
brain metastases to whole-brain radiotherapy, a diffusionmapping technique has been developed at the University
of Wisconsin that allows the reliable comparison of intraand post-treatment images with pre-treatment images on a
voxel-by-voxel basis (32, 33).
An example for one patient is shown in Figure 4; green
points on the graph indicate no change in ADC for a voxel
from the baseline to the assessment time point, red points
indicate that the ADC has increased at the assessment
time point as compared to the baseline and blue points
indicate that the ADC has decreased from the baseline. An
increase in ADC (red points) in a voxel indicates increased
diffusion distance of the water molecules, and hence a
decrease in cell density, which could indicate that the volume is responding to therapy. In the same way, no change in
ADC (green points) could indicate no response to therapy,
and a decrease in ADC (blue points) indicates a decreased
diffusion distance of water molecules, and hence an increase
in cell density, which could indicate a proliferating volume
of cells during therapy.
Another brain technique can be used to adopt a conformal
avoidance strategy. Functional MRI (fMRI) has been incorporated into the TPS to consider defining various functional
organs at risk (fOAR). Work has also looked at the robustness of this technique in terms of recommending planning
margins of uncertainty (11). The benefits of including such
information remain to be proven, but results show that several primary functional areas can be included in the planning
prescription without any adverse changes to the planning target volume (PTV) coverage (12, 34).
In the setting of brain metastases, investigation on the utility of DW-MRI for assessing response to therapy has been
limited. Goldman et al. have studied diffusion-weighted MRI
in 15 patients who underwent gamma-knife radiosurgery for
brain metastases, and demonstrated the potential for early
changes in mean ADC to predict therapeutic response (35).
However, their assessment of changes in mean ADC was
obtained by averaging over an entire metastatic lesion, not by
using a voxel-by-voxel approach. One potential disadvantage
of mean ADC is that different areas of tumor with increasing and decreasing changes in diffusion could cancel out,
such that there would be no observed change in overall mean
ADC, thus decreasing sensitivity.

Figure 3: Visualization of the right trigeminal nerve root using FIESTA
MR imaging. The arrow points to the right trigeminal nerve root.

Some MRS data can be incorporated into TPS. Some degree
of expertise is required in incorporation into planning as use
of this data is still in its infancy (36, 37)
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Figure 4: MR images at various stages of radiotherapy: (A) before radiotherapy, (B) mid-treatment and (C) post-treatment. The graphs in B and C show the
voxel-by-voxel ADC values changing as determined during ADC image analysis on MRI. Green points on the graph indicate no change in ADC for a voxel
from the baseline to the assessment time point, while red points indicate that the ADC in a voxel has increased compared to the baseline, and blue points indicate that it has decreased compared to the baseline.

Head and Neck
Historically, the sensitivity of FDG PET was generally
reported as higher than conventional MRI scans for detecting
lymphogenic metastesis in head and neck cancer patients. For
example, Braams et al. (38) reported for FDG PET a sensiti
vity of 91% and specificity of 88%. In contrast, a sensitivity
of 36% and a specificity of 94% were calculated for MRI
using T1- and T2-weighted scans.
However, with the advent of specialised RF coils for imaging in treatment shells, the use of advanced signal-hungry

MRI sequences has improved markedly. With specialised
RF coils patients can also undergo MRI in the treatment
position, improving the accuracy of any image registration.
Figure 5 shows a typical treatment coil for head and neck
MRI scanning.
Vandecaveye et al. (15) scanned a 26-patient cohort with persistent or recurrent head and neck squamous cell carcinoma
(HNSCC). Compared with histopathologic findings, they
showed a sensitivity and specificity of around 95% using
ADC analysis. In comparison T1- and T2-weighted MRI
scans of b0 (s/mm2) images gave a specificity and sensitivity

Figure 5: Photograph showing the set-up for head & neck planning on a wide-bore MRI scanner. A flat tabletop is used in conjunction with the standard
thermoplastic immobilization shell. Two dedicated RF surface-coil arrays are placed laterally around the shell to enable high-quality imaging in the treatment
position.
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of approximately 65%, while b1000 images scored a sensitivity and specificity of about 72%. When compared with computed tomography, TSE-MRI and FDG-PET, the DW-MRI
sequence analysis yielded the highest sensitivity and specificity with fewer false-positive results in persistent primary site
abnormalities and in persistent adenopathies, and aided in the
detection of nodal metastases that were indicated as smaller
than 1cm diameter.
There can be advantages in registering and overlaying FDG
PET images with MRI or CT contours. Nishioka et al. (39)
showed that the PET scans could be used to confirm whether
parotid sparing was appropriate by analysing uptake. The
PET also confirmed that the total number of positive nodes
in the 21 patients was increased from 28 by physical examination coupled with CT/MRI to 39 by the image fusion of
the PET scans with the MRI/CT. The recent introduction of
combined PET-MRI gantries represent a new exciting area
of clinical research into analysing the potential advantages of
combining these imaging data sets, which will have similar
acquisition time stamps.
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often made to supplement identification of breast tissue by
palpation and delineating on the patient with radio-opaque
catheters when undergoing CT scanning. Giezen et al. (50)
performed an exploratory study of MRI versus CT for delineation of breast volume for the purpose of radiotherapy
planning. In a small study of 15 patients and four volume
delineators, it was observed that MRI detected breast glandular tissue beyond that identified by CT scanning, especially
in the cranial direction, and that this tissue may be conventionally missed geographically if CT planning is relied on
to delineate volume. The clinical uncertainty is whether this
“missed” tissue is seen in a larger cohort of patients and
observers. The current very good local control rates for breast
conservation radiotherapy in general do pose the question of
whether these differences in volume make any difference to
clinical outcome. Recurrence rates are still significant, especially in younger patients (51) who have denser breasts, and
this may be a cohort that benefit most from better volume
delineation. Their findings therefore warrant further examination. Figure 6 gives an example of a typical breast image
taken of a patient lying prone in breast coils.

Breast abnormalities are visible on MRI using both non-
contrast and contrast-enhanced MRI scans. MRI has been
shown to have greater sensitivity than mammography for
assessment of extent of breast cancer under certain clinical
conditions (40-48), making MRI a potentially interesting tool
in the appropriate planning of radiotherapy.

One difficulty for MRI planning in the breast is the
contradictory patient set-ups: treatment is performed in the
supine position, whereas optimum imaging is performed with
the patient lying prone and the breasts suspended in separate
wells of the RF coil. Although MRI of sufficient quality can
be obtained in the supine position using a body coil array,
the breast tissue is then positioned further from the isocenter,
causing issues with geometrical accuracy (52).

The purpose of standard post-operative tangential radiotherapy following wide local excision for early breast cancer is to treat the remaining breast volume. However, the
breast volume is poorly defined by CT (49), and attempts are

An emerging trend is to treat some patients with favourable
histology with partial breast radiotherapy directed to the site
of the surgery only. Clinical studies are currently underway.
Kirby et al. (53) assessed breast-cancer patients positioned

Breast

Figure 6: MR image of breast showing irregularities (anatomical right breast). Most breast images are obtained using breast surface coils to reduce
the s ignal-to-noise ratio, and the patient is usually positioned prone in the coils. This image is courtesy of the Aroura web site (www.Aroura.com).
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prone to determine the value of MRI and CT for planning
partial breast irradiation (PBI) to the tumor bed (TB). They
found that TB volumes delineated using fused MR and CT/
clip data were discordant to those delineated using CT/clips
alone. However, resulting clinical and planning-target volumes were sufficiently concordant to ensure adequate coverage of the target volume using the CT-based tangential
treatment fields in 26 of 30 cases, suggesting that the use of
MRI for most cases did not lead to a substantial change in
treatment volume. Two of the 30 cases showed inadequate
coverage due to discordance between volumes, both inferiorly. Another two of the 30 cases showed that inadequate
coverage was related to the target volumes being located at
the peripheries of breast tissue, where coverage is difficult
due to the complex 3D shape of breast tissue. This study suggests that MRI may only have a limited role to play in delineation of the TB post-operatively when CT data with clips
defining the TB is available.

9
soft-tissue contrast. MRI scans can be undertaken in a similar
position to that used for radiotherapy treatment.
Figure 7 shows a T2-weighted single-shot fast-spin echo
(SSFSE) image of a small-cell lung cancer. There is excellent
differentiation between mediastinum and tumor mass, while
the boundary between tumor and consolidation is less clear.
Of particular interest for defining radiotherapy treatment
volumes for lung cancer is the ability to accurately determine lung-cancer motion. MRI is becoming an increasingly
attractive modality to image this motion. Parallel imaging

However, there may be a role in the future for defining the
TB pre-operatively using MRI as the imaging modality of
choice. The study reported by Schmitz et al. (54) compares
breast MRI with pathology to assess treatment margins in 62
patients. While the MRI-estimated GTV showed close concordance with the pathologic samples, these samples also
showed significant spread of occult pathology. The findings
report that for MRI-guided minimally invasive therapy, typical treatment margins of 10 mm around the MRI-GTV may
not incorporate occult disease in 52% of patients. When surgery achieves a 10 mm tumor-free margin around the MRIGTV, radiotherapy to the TB may require clinical target
volume margins of greater than 10 mm in up to 25% of the
patients. The outcome from breast-conservation studies does
not suggest such a high recurrence rate as might be predicted
by these figures, but may perhaps identify patients who might
be at greater risk of recurrence. Correlation of tumor extent
with breast recurrence rates will be required.
Ultra small particles of iron oxides can act as a negative contrast agent and are taken up by normal tissue on T2* weighted
sequences. Their sensitivity and specificity for detecting
nodal metastases is high (55). These allow detection of
micrometastases in the nodes as small as 2 mm in diameter.
New promising agents such as ferumoxytol are under investigations for FDA approval.
Lung
CT scans with the addition of FDG PET is the standard of
care for diagnosis of lung cancer; however, there is poor distinction between structures with similar electron densities,
making it difficult to differentiate lung cancers from surrounding lung collapse, consolidation or effusion. MRI can
enable differentiation of these situations through improved

Figure 7: Axial, coronal and sagittal plane of a T2-weighted single-shot
fast-spin echo image of a small-cell lung cancer for a 64-year-old male with
T4 N2 M0 disease. There is excellent differentiation between the mediastinum and tumor mass, although the boundary between the tumor and the consolidation is unclear. (Images done on 1.5T GE scanner, with inspiration
breath-hold.)
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techniques improve both spatial and temporal resolution.
There are two particular sequences useful in imaging motion:
fast low-angle shot (FLASH) sequences and true fast imaging with steady-state precession (TrueFISP) sequences.
Plathow et al. (56) investigated these two imaging sequences
to quantify tumor mobility in 20 patients with Stage I non
small cell lung cancer (NSCLC). Both techniques showed
regular, synchronous diaphragm and chest-wall motion of
diagnostic quality. The TrueFISP sequence acquired three
images per second, allowing for continuous recording during
the respiratory cycle, and correlated well with the FLASH
sequences, which acquired 10 images per second. There were
no significant differences in measurement of tumor mobility
between the techniques; however, the signal-to-noise ratio
was superior for TrueFISP.
Other sequences used to image motion include a multislice breath-hold steady-state free-precession sequence and
dynamic 3D free-breathing fast-field echo planar imaging
(FFE-EPI). Blackall et al. (57) used these sequences to evaluate 3D geometric errors associated with respiratory motion
variability in 10 volunteers and five lung-cancer patients. The
protocols were optimized for each participant by adjusting
the voxel size, to obtain coverage of the entire lung at the
highest possible resolution while maintaining an acceptably
short acquisition time. The participants were coached to help
them regulate breathing. Images were acquired throughout
the respiratory cycle and registered to demonstrate motion
using different models. Respiratory-motion models based on
rapidly acquired free-breathing MRI data showed reasonably
good levels of inter-cycle reproducibility, with mean errors
at the lung surface in the range of 1.7 to 3.9 mm for healthy
volunteers, and 2.8 to 3.3 mm for lung-cancer patients. Interand intra-cycle variability were less during exhalation.
Dynamic MRI can thus be used to define a patient-specific
ITV for planning of lung cancers for radiotherapy. It allows
the entire lung volume to be imaged fast enough to analyse
true motion and deformation over the breathing cycle, while
the patient breathes freely, as occurs during radiotherapy
treatment. MRI studies using TrueFISP sequences have
shown that lower-lobe tumors move more than upper- or
middle-lobe tumors, and that the movement of tumor-bearing
lung is reduced compared to normal lungs (12, 58) . The latter is also dependent on tumor diameter, with less movement
seen in larger tumors (58). However, dynamic MRI of the
lung is prone to artefact, which affects registration accuracy
for the purposes of radiotherapy planning.
Dynamic MRI imaging of lung cancers can be used for probability density function (PDF), planning whereby the dose
distribution of radiotherapy is modulated by the probability that the target occupies that location. In a study using
17 healthy volunteers and lung-cancer patients, Cai et al. (59)
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developed a technique to measure this using TrueFISP
sequence. Improvement in PDF reproducibility was observed
with increased imaging duration and a greater number of
sampled breathing cycles. Two patient-specific imaging
acquisitions were recommended to establish the reproducibility of the PDF if PDF-based treatment planning was being
considered.
The current standard of 4DCT is not as accurate in determining the tumor-motion PDF. It has lower temporal
resolution, particularly in detecting craniocaudal motion.
The tumor-motion trajectory is measured from segments
of numerous breathing cycles rather than a single breathing cycle. To take true respiratory motion into account for
radiotherapy planning and treatment the entire organ needs
to be imaged at high speed while the patient breathes normally. This is not possible with 4DCT. Variability in respiratory motion from one cycle to the next can be magnified
in 4DCT images, leading to artefacts. It cannot image the
statistically needed number of complete breathing cycles for
a reproducible PDF.
There have been no definitive contouring studies comparing the delineation of lung cancer on MRI to CT or PETCT scans. As a diagnostic tool in differentiating benign from
malignant nodules, techniques such as DWI have shown similar accuracy to PET scans (60). DCE-MRI has shown some
promise in differentiating between subtypes of lung cancer in
inoperable cases (61). This may have an impact on determination of CTV margins and type of chemotherapy delivery
in cases where histological subtype has not been determined
by biopsy.
The use of MRI to avoid normal tissues in lung-cancer
radiotherapy planning is an emerging area of research. This
is possible with the use of inert hyperpolarized helium-3
gas, which is inhaled to demonstrate regional lung function
by selective display of ventilated air spaces. Non-ventilated
regions show up as signal voids. Bates et al. (62) contoured
functional lung based on helium MRI on seven patients
with Stage III NSCLC (14). Two IMRT plans were created:
the first to minimise total lung volume receiving >20 Gy
(V20) and the second to minimise functional lung volume
receiving >20 Gy (fV20). In all patients, the addition of
functional information reduced both V20 and fV20 without
compromising target coverage. The median reduction in
V20 was 1.5% and fV20 2.7%; however, mean lung dose
was not significantly different. Larger reductions were seen
if the non-functional lung was 25% of total lung volume.
Similarly, Ireland et al. (63) observed a median reduction
of 1.6% in V20 and 3.1% in fV20 in six plans. The greatest
benefit was seen if functional lung lay in the path of the
beam and could therefore be spared by alternative beam
arrangements.
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MRI scans can be used to evaluate changes in lung tumors
and normal tissue response during a course of radiotherapy. Yankelevitz et al. (64) performed 0.6T MRI scans
before, during and after radiotherapy in 10 patients. After
20 Gy tumors decreased by 38%, and after 40 Gy by 64%.
All patients showed increased signal intensity in normal
lung tissue during radiotherapy but without clinical evidence of radiation pneumonitis. This increased up to six
months after radiotherapy before decreasing. Other authors
have noted changes in tumor vascular permeability on
DCE-MRI during treatment, reflecting changes in microvascular structure (65). MRI has the potential to allow
adaptive radiotherapy planning in response to changes during treatment.
Finally, MRI may be used as a prognostic tool for treatment outcomes. Ohno et al. (66) performed post-treatment
DCE-MRI scans in 114 evaluated patients who had chemoradiotherapy for Stage III NSCLC. A breath-hold technique
at end-inspiration was used. Patients were divided into
two groups for analysis: those with local control and those
with local failure. Signal-intensity time curves of the tumor
and normal lung were created and evaluated. Survival was
compared above and below an adopted threshold value for
dynamic MRI index. An 11-month difference in survival was
noted between the two groups. However this has not been
compared to other imaging such as PET scans.
Prostate
The use of MRI for diagnosis of prostate cancer is not currently standard; however, MRI is recognised as a superior
imaging modality in defining the prostate volume accurately,
and, with advanced techniques such as MRSI, has the ability
to distinguish between the cancer volume and normal prostate tissues.
Prostate scans may be acquired in the treatment position
using a flat tabletop and a posterior RF coil placed underneath it without too much loss of quality (67). A support over
the body can be used to avoid compression from the anterior
RF coil if required. Any residual distortion at the skin surface can be largely ignored or a smaller FOV acquired and
matched to sufficient bony anatomy in the CT.
A clear indication for MRI is in cases of bilateral hip replacement; Rosewall et al. (68) showed that smaller prostate volumes were delineated on the MRI compared to CT, which is
adversely effected by high Z artefacts. In contrast, there is no
effect from the susceptibility artefacts on the MRI, which are
confined to within the prostheses.
For gold-seed localization as used in image guidance for intact
prostate radiotherapy, the MRI exam sequence may include a
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gradient echo-based sequence that improves the visualization
of the markers by virtue of susceptibility artefacts.
Khoo et al. (69) undertook a five-patient cohort study to compare contour segmentation of structures in the prostate region.
Using a subjective scoring system, they concluded that MRI
was superior to CT when observers were segmenting the
prostate apex and rectum. The FLASH 3D sequence showed
the best images, as no volume averaging was involved with
this sequence.
Haider et al. (70) studied 33 prostate patients with suspected
relapse after external beam radiotherapy. They compared
T2-weighted with dynamic contrast enhanced (DCE) MRI
scans, concluding that DCE-MRI performed better than
T2-weighted imaging in the detection and localization of
prostate cancer in the peripheral zone after EBRT. This finding may be helpful in the planning of salvage treatments.
McLaughlin et al. (71) explored the premise that vessels
involved in erectile function – the corpus cavernosum (CC)
and the internal pudental artery (IPA) – may be affected by
radiation, based on proven radiation effects to other vasculature structures in the body. They studied 25 patients undergoing radiotherapy, 10 external beam and 15 brachytherapy
patients. MRI T2 sequences (axial, coronal and sagittal) were
obtained with a pelvic coil. Of these patients, 10 were entered
on a vessel-sparing protocol and underwent treatment-
planning CT. In addition, a non-contrast MRI angiogram
was obtained to define the IPA. The proximal CC was clearly
defined on axial and coronal T2 MRI. Hence they showed the
potential of MRI to visualize the prostate and erectile structures. They registered the MRI data sets by mutual information and created radiotherapy treatment plans that allowed
dose limitation to the critical erectile tissues (the CC and
IPA) without compromising target coverage. While these
structures are visible with MR angiography, the researchers
suggested that coronal images using conventional MRI T2
sequences provide sufficient detail of the outline and position of these vessels for conformal avoidance in radiotherapy.
They predicted that it erectile vessel-sparing radiotherapy
may have as favourable an impact on sexual potency after
radiation as nerve-sparing prostatectomy.
McLaughlin et al. (71) also includes useful data on distances from the prostate apex to the penile bulb. While the
mean range in their sample was 1.45 cm, they observed
ranges in distance between these structures of between
0.7 and 2.1 cm. This suggests that the standard distance
of 1.5 cm used with CT images may sometimes over- or
underestimate distance from the apex to the vascular structures. They suggested that the use of this rule would have
underestimated the distance in one half of their patient
cohort, potentially leading to marginal miss. The prostate
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volume would have been overestimated in the other half of
their patients, limiting the degree to which erectile tissue
was spared in these patients.

normal tissues (77-79). MRI has been the imaging modality
of choice for radiotherapy delineation for a number of clinical trials (79).

The argument for MR images in combination with CT for
prostate radiotherapy treatment planning is compelling.
However, issues remain for some of the functional techniques previously described to be used in treating the prostate. The requirement of sufficient signal-to-noise in MRSI
for example, usually demands the use of endorectal receiver
coils, which distort the prostate compared to its position on
CT acquisition. Remedies to this include higher field strength
and/or less invasive coil designs.

MRI sequences for radiotherapy delineation purposes are
usually T2-weighted (80-83). The choice of coil has varied
throughout the literature, with details often not provided;
however, when described, generally in more recent investigations (84), it was usually a body coil with phased array
coils. Similarly, patient positioning is often not detailed in
the literature; however, a number of studies have achieved
MRI scanning positions that mimic treatment position,
including a flat couch top (82, 83, 85). The significance of
treatment positioning in cervix MRI scanning for radiotherapy has not been assessed. The field of view (FOV) used
for cervix MRI for radiotherapy purposes also varied, ranging from covering only the target and surrounding nearby
regions (83) to encompassing the majority of the patient
volume (84).

The evolution of multiparametric combinations of MRI
sequence information, for example combining information
from T2w, DCE, DW 1/2 MRS is rapidly growing in prostate cancer detection and mapping. It increases the power
of MRI over each single sequence. This may be of value in
the context of radiotherapy-planning. Moreover, preliminary
data on hybrid PET/MRI suggests that Choline/ADC maps
could more accurately predict tumor staging and mapping.
Multimodal imaging or multiparametric MRI could play a
major role in the context of focal therapies or focal dose
escalation (72).
Blood oxygenation can be monitored non invasively with
MRI potentially providing information regarding tumour
hypoxia. Blood oxygen level dependent (BOLD) sequence
studies have shown a direct correlation between measurements of oxygen using an Eppendorf electrode and R2*
relaxation time. These parameter maps can highlight areas
that are likely to be radioresistant and requiring a boost in
dose (73).
Cervix
MRI is well established as the optimum imaging modality for
cervical-cancer diagnosis in comparison to CT and clinical
examination (74, 75). Challenges in determining the extent
of cervical cancer are in detecting stromal invasion (74, 75)
and establishing lymph-node status. Detection of lymphnode invasion is currently most accurate with FDG-PET
imaging. However, the accuracy of MRI has been improved
with ultrasmall superparamagnetic iron oxide particles that
are lymph-node specific contrast agents (76); future research
may improve this further.
Use of MRI for radiotherapy treatment planning, monitoring of tumor response over the course of treatment and
assessment of relapse following treatment has been investigated for over a decade. MRI is considered the imaging
modality of choice for radiotherapy contouring, with significant improvement in contrast between the target volume and

A number of other MRI sequences have been considered for
the purpose of radiotherapy target volume definition and treatment response assessment, including T1-weighted sequences
with and without fat suppression (81, 82, 86). Recently the
use of diffusion-weighted imaging and ADC values has been
investigated as a potential tool for predicting and monitoring
treatment response (84, 87). Although use of ADC values for
determining patients likely to respond well to radiotherapy
has not yet been well established, early work is promising
and warrants further investigation.
Following guidelines published in 2006 (88), MRI is being
increasingly used in image-guided brachytherapy (IGBT) of
the cervix. MR-compatible applicators made from materials
such as titanium or plastic can be imaged safely in vivo with
little susceptibility to artefacts using fast spin-echo based
protocols. Work is currently being carried out to improve the
visualization of these applicators on MRI using short or even
ultrashort TE sequences.
Discussion
Use of MRI for radiotherapy treatment planning is well
established for many treatment sites such as brain and head
and neck, with its use in many others under investigation.
There is a growing body of literature considering the use of
MRI for radiotherapy treatment planning. As noted in section one of the results, a large and growing number of MRI
sequences have been considered for the purposes of radiotherapy treatment planning. T1 and T2 scans are commonly
used in many treatment sites. The use of DWI is showing
promise in a number of clinical areas for establishing nodal
involvement, and thus target volume, as well as for considering response assessment.
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MRI has a proven track record in brain function studies. MR
sequences in the brain aid in the diagnosis and staging of
brain tumors (e.g., glioma). Early studies show a correlation
between tumor activity and DW images using fDM analysis
methods. In some non-malignant diagnosis such as AVM and
the trigeminal nerve in Neuralgia patients, specialized MR
techniques (e.g., MR angiography) have been used to provide
exquisite targeting information for stereotactic radiosurgery
applications.

CT. This can lead to more accurate and precise outlining of
the GTV using the MRI images than CT alone. T2 and DCE
MRI imaging techniques aid in diagnosing sites of potential
relapse. Vascular structures such as the corpus cavernosum
internal pudental artery (IPA) that are involved in erectile function can be visualized using MR angiography and
conventional coronal MRI imaging methods. These may be
potential sites for conformal avoidance in future radiotherapy
treatment regimens.

MRI has been used in combination with PET scan and CT
in head and neck treatment. Standard MRI techniques show
the soft-tissue boundaries in this region, while PET has
been effectively used to track regions of high activity that
have high specificity to potential nodal involvement. DWMRI using ADC methods shows promise in differentiating
regions of tumor recurrence. There is a very high correlation
in specificity and sensitivity when compared with pathological samples.

Use of MRI for the purposes of radiotherapy treatment planning, monitoring of tumor response over the course of treatment and assessment of relapse following treatment has
been investigated for over a decade. Use of MRI for the purposes of radiotherapy contouring is considered the imaging
modality of choice, with significant improvement in contrast
between the target volume and normal tissues. MRI has been
the imaging modality of choice for radiation therapy delineation for a number of clinical trials involving the cervix
cancer-treatment site.

MRI has shown the potential to provide a more accurate
picture of the GTV, compared with current methods such as
CT. When combined with pathological analysis, surprisingly
large treatment margins are sometimes required. One study
has found that when surgery achieves a 10 mm tumor-free
margin around the MRI-GTV, radiotherapy to the tumor bed
may require clinical target-volume margins of greater than
10 mm in up to 25% of patients (54).
The future use of MRI may have an impact on discerning
which clinical stages are suitable for partial breast irradiation
techniques. The use of MR seems to indicate more regions
of abnormality post-surgery and prior to other interventions.
This may indeed have a major impact on cancer management into the future. It is not clear yet that there is an MRI
technique that can discern breast tissue from other tissue.
But it does seem clear that breast anomalies in and around
the excised tumor bed are highlighted with subsequent MRI
imaging.
MRI has huge potential in radiotherapy treatment of lung
cancer. It has a role in diagnosis, tumor delineation, measurement of motion and identifying functional normal tissues to
avoid. It can also be used during radiotherapy to allow potential treatment adaptation in response to changes occurring in
the lung tumor and surrounding normal tissues. Its superior
soft-tissue contrast and lack of ionizing radiation compared
to CT makes it an attractive imaging modality, particularly
for repeated imaging. However, there are still hurdles to be
overcome, a major one being the lack of electron-density data
for radiotherapy planning.
Anatomical structures within the prostate such as the apex
and the seminal vesicles are more clearly visible on MRI than

The debate over what field strength is optimum for MRI
simulation remains inconclusive. Dedicated MR scanners
for RT planning are presently being installed at both 1.5 and
3.0 Tesla. The utilization of MRI will certainly have a bearing on this; the soft-tissue anatomical delineation benefits are
adequately provided for at 1.5 Tesla. However, the increase
in signal-to-noise, which doubles by going to 3.0 Tesla, is
important in signal hungry applications. This may be particularly useful for the functional techniques and in following treatment response. Generally imaging in the body is
made more difficult at higher field strength due to increases
in several artefacts and dielectric effects. Some of the RF
homogeneity issues of the latter are now solved with the vendors providing dual transmit technology. Over the proceeding years those centres that have elected to install 3.0 Tesla
should be able to provide data to make the optimal choice
clearer.
Use of MRI for radiotherapy treatment planning is commonly undertaken to supplement CT imaging; this is still the
standard of care. Radiotherapy treatment planning with MRI
alone presents two challenges: the determination of electron
density as required for accurate radiotherapy dose calculations; and geometrical accuracy. MRIs do not inherently
provide any information on electron density and, particularly
towards edge of the bore, may show significant distortion. A
number of approaches have been undertaken to address these
issues, with a methodologies being developed for radiotherapy treatment planning using MRI alone.
With the introduction of MRI-linear accelerators and the
potential for real-time adaptive radiotherapy, geometric accuracy and electron-density accuracy will require
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further investigation as treatment margins are reduced
and the impact of geometry and dose-calculation errors is
increased. The (ViewRay™) MRI-Cobalt machine is likely
to give us the first window into how successful MR will be
as an online image guidance modality. Sagittal images can
be acquired using a fast 4 frame per second planar treatment scan that is based on the TRUFI (true fast imaging
with steady state precession) sequence (89) known to provide the best SNR at very high speed among the existing
fast imaging sequences. TRUFI is a type of fast gradient
echo sequence (90).
Currently there are two working MRI-Linac prototypes. These
include a modified 6 MV Elekta accelerator merged with a
modified 1.5 T Philips Achieva MRI system with the linac
beam transverse to the magnetic field (4). The transverse field
approach results in numerous dose perturbation effects including the electron return effect, lateral dose shifting, cavity under
and overdosing (91-93), and potentially large entry and exit
skin dose increases (94, 95). These effects are reduced at low
magnetic fields and multiple beam angles reduce the impact
of skin dose. The other prototype includes a 6 MV accelerator
merged with a biplanar, low field MRI (3, 96), whereby the
linac and magnets can both rotate, hence enabling the linac
beam to be in line with the magnetic field. This potentially
also involves enhanced skin dose (5) from focused contamination. However clever design of the magnet may reduce this
effect (97).
Conclusions
MRI has a proven role in stereotactic targeting in the brain;
the potential for enhanced application of MRI in radiotherapy
treatment planning to other cancer treatment sites in the body
represents an exciting area of further research that deserves
exploration. In the future the increased availability of dedicated scanners combined with the lack of ionising radiation
make treatment planning using MRI alone a realistic and
desirable prospect.
Experience has already shown that MR-only planning is
feasible in brain (98), prostate (99) and several other areas
(100). Developments in imaging sequences and bone-tissue
segmentation combined with the production of good-quality
pseudo-DRRs for patient set-up are all being investigated to
further enhance this work. The logical progression of this
MRI-guided strategy is the clinical prototyping of hybrid
MRI-linear accelerator systems that will provide the ultimate
in adaptive radiotherapy.
We hope this description of various MRI techniques applied
to clinical trials indicates a pathway forward for enhanced
use of MRI in TPS, leading perhaps to improved therapeutic ratio for patients and improved patient management in
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general. The breadth and scope of MRI sequences and analysis techniques is such that they can be considered analogous
to opening a box of chocolates. One is never quite sure what
is in the box but usually one is surprised by the sweetness of
the outcome.
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